Raevuori Anu, Lukkariniemi Laura, Suokas Jaana T, Gissler Mika, Suvisaari Jaana M, Haukka Jari
Clinicum, Department of Public Health, University of Helsinki, Finland.
Department of Adolescent Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.
Int J Eat Disord. 2016 Jun;49(6):542-52. doi: 10.1002/eat.22497. Epub 2016 Feb 15.
We examined the use of antimicrobial medication as a proxy for infections in large patient cohort treated for binge-eating disorder (BED), bulimia nervosa (BN), and anorexia nervosa (AN) over the five-year period preceding eating disorder treatment.
Patients (N = 1592) at the Eating Disorder Unit of Helsinki University Central Hospital between 2000 and 2010 were compared with matched general population controls (N = 6368). The study population was linked to the prescription data of antibacterial, antifungal and antiviral medication from the Register on Reimbursed Prescription Medicine. Data were analyzed using regression models.
Individuals with BN and BED had received more often antimicrobial medication prescriptions compared to their controls (OR: 1.7, 95% CI: 1.3-2.1; OR: 2.6, 95% CI: 1.4-4.6, respectively), while no significant difference emerged in AN (OR: 0.9, 95% CI: 0.7-1.0, p = 0.10). Of the main drug categories, the respective pattern was seen in antibacterial and antifungal medication, while increased use for antivirals appeared only in BN (OR: 1.6, 95% CI: 1.1-2.3). Measured with the mean number of prescriptions or mean Defined Daily Doses per individual, patients with BN, BED and males with AN had also higher total antimicrobial medication use.
Indicating increased infections, we found elevated use of antimicrobial medication in BN, BED and in males with AN. Infections may be consequence of hyperglycemia, weight gain, or dysregulation of intestinal microbiota associated with core eating disorder behaviors. Or the other way round; changes in intestinal microbiota due to infections, inflammation, or antibacterial medications might contribute to eating disorders in multiple ways. © 2016 Wiley Periodicals, Inc. (Int J Eat Disord 2016; 49:542-552).
我们研究了在饮食失调治疗前的五年期间,将抗菌药物的使用作为患有暴饮暴食症(BED)、神经性贪食症(BN)和神经性厌食症(AN)的大型患者队列中感染情况的替代指标。
将2000年至2010年期间赫尔辛基大学中心医院饮食失调科的患者(N = 1592)与匹配的普通人群对照组(N = 6368)进行比较。研究人群与报销处方药登记册中的抗菌、抗真菌和抗病毒药物处方数据相关联。使用回归模型分析数据。
与对照组相比,患有BN和BED的个体更频繁地接受抗菌药物处方(OR分别为:1.7,95%CI:1.3 - 2.1;OR:2.6,95%CI:1.4 - 4.6),而AN患者中未出现显著差异(OR:0.9,95%CI:0.7 - 1.0,p = 0.10)。在主要药物类别中,抗菌和抗真菌药物呈现出各自相应的模式,而抗病毒药物使用增加仅出现在BN患者中(OR:1.6,95%CI:1.1 - 2.3)。以每个个体的处方平均数或平均限定日剂量衡量,患有BN、BED的患者以及患有AN的男性的抗菌药物总使用量也更高。
表明感染增加,我们发现BN、BED患者以及患有AN的男性中抗菌药物使用增加。感染可能是高血糖、体重增加或与核心饮食失调行为相关的肠道微生物群失调的结果。或者反之;由于感染、炎症或抗菌药物导致的肠道微生物群变化可能以多种方式促成饮食失调。© 2016威利期刊公司(《国际进食障碍杂志》2016年;49:542 - 552)